Abstract CN14
Background
This study is part of the implementation of m-Health in outpatient Clinical Pharmacy at Hospital of the Principality of Andorra, with the aim of knowing the qualification of the Abeona Health App by the patient when using it for three months. The main objectives are: 1. Determine the general rating of the App according to the patient. 2 and 3. Know if the patient would continue using the App for one year and if they would recommend the App.
Methods
Cross-sectional study in onco-haematological patients under treatment with OAAs. 1. Inclusion criteria: all adult patients treated with OAAs seen from November 2022 to May 2023 (6 months of study). 2. Tool measure: the validated spanish translation of uMars survey was chosen to meet the research objectives. 3. Data collected from the patients: age, sex, type of tumour and type of OAAs. 4. Data collected from the surveys: the uMARS questions that were used to evaluate the Abeona Health App were: 2.4, 5, 6, 7, 8, 9, 10, 11, 12, 17, 18, and 20. 5. Statistical analysis: descriptive, performed with the Jamovi statistical package. 6. Ethical aspects: before providing the surveys, the patients were informed that their data would be treated anonymously, and they gave their signed informed consent to participate.
Results
64 patients were visited. 44 participated in the study (4 of them through their children for not knowing how to use an App). 41 were women (64%) and 23 men (36%) with a mean age of 63 years. The most frequent tumor in women was the breast with OAAs Palbocilic and in men the Colon with Capecitabine. The general quality of the App according to the patient's response in the uMars survey was: 7.7% of the patients scored 3, 50% scored 4 and 42.3% scored 5. When referring to the use of the App for a year, 19.2% of the patients responded from 3 to 10 times, 46.2% from 10 to 50 times, and 34.6% more than 50 times. In relation to whether patients would recommend the App, 30.8% of the patients answered that they would recommend it to many people and 69.2% that they would recommend it to everyone.
Conclusions
1. The Abeona Health App was rated with a score of more than 4 for 92.3% of patients. 2. The 80.8% of patients would continue using it for a year. 3. The 100% of patients would recommend it to people who could benefit from it.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
CN9 - Communicating with patients in modern cancer care
Presenter: Alison Woods
Session: Poster session 25
Resources:
Abstract
CN10 - Development and usability test of an individualized nutrition management application (iNutrition) for post-discharged gastric cancer patients following gastrectomy
Presenter: Xiao-han Jiang
Session: Poster session 25
Resources:
Abstract
CN11 - Improving quality of life for patients with prostate cancer: ProstaGYM, a new digital skill
Presenter: Enrique Gallardo
Session: Poster session 25
Resources:
Abstract
CN12 - Integrating weekly symptom monitoring for patients with prostate cancer in radiation oncology: A prospective cohort study using electronic patient-reported outcomes
Presenter: Pia Møller
Session: Poster session 25
Resources:
Abstract
CN15 - Real-life clinical and organizational evaluation of telemonitoring and assisted telemonitoring in more than 1500 cancer patients
Presenter: Sophie Martin
Session: Poster session 25
Resources:
Abstract
CN16 - The Mount Vernon Cancer Center non medical prescriber GI oncology clinic experience
Presenter: Melanie Blyth
Session: Poster session 25
Resources:
Abstract
CN17 - Use of the ONCO'nect telemonitoring tool by socially deprived outpatients actively treated for a solid cancer: A retrospective quantitative and qualitative analysis of the Re'connect program
Presenter: coralie BOITEAU
Session: Poster session 25
Resources:
Abstract
CN20 - Nurse’s role in coordinating new cancer screening initiatives: Experiences from an on-going risk-based lung cancer screening feasibility study, among Swedish women
Presenter: Nina Nordgren
Session: Poster session 25
Resources:
Abstract
CN21 - Stakeholder perceptions of cervical screening accessibility and attendance in Ireland: A qualitative study
Presenter: Sophie Mulcahy Symmons
Session: Poster session 25
Resources:
Abstract
CN22 - Survivorship care in melanoma cancer survivors
Presenter: Riley Fadden
Session: Poster session 25
Resources:
Abstract